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Background: Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin’s lymphoma
often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed.
MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy.
Methods: We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer
antigens that can be targeted to dendritic cells (DCs) via CD40.
Results: Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Cyclin
D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific
CD8+ T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to
human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion
protein expanded a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells.
Conclusions: This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin
D1 to DCs provides a new strategy for mantle cell lymphoma vaccine.
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Mantle cell lymphoma (MCL) is a distinct clinical subtype
of B cell non-Hodgkin’s lymphoma (NHL) and accounts for
approximately 5%–10% of all lymphoma cases. Current
treatment is based on standard chemotherapy often com-
bined with monoclonal antibody rituximab, followed by
hematopoietic stem cell transplantation [1-3]. Although
these treatment regimens can induce a high rate of remis-
sion, most patients ultimately relapse and cannot be cured
[4,5]. Therefore, new therapeutic strategies are needed to
improve the overall survival of patients and decrease
treatment-associated morbidity.
A key common transforming event in the pathogenesis
of MCL is chromosomal translocation t (11; 14) (q13;
q32) leading to overexpression of cyclin D1. Cyclin D1 is
a cell cycle regulator that is crucial for the G1-S* Correspondence: jtchen@jlu.edu.cn
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unless otherwise stated.transition. Its overexpression may facilitate the malig-
nant transformation of the lymphoid cell and tumor pro-
gression, resulting in the deregulation of cell cycle
control by inhibiting the suppressor effect of retinoblast-
oma 1 (RB1) and the cell cycle inhibitor p27 [6-8]. Al-
though cyclin D1 negative cases have been reported
[9-11], cyclin D1 overexpression still is considered a
hallmark for MCL [12]. In addition to MCL, cyclin D1
has been detected in a wide variety of lymphoid and
myeloid malignancies, including multiple myeloma,
acute lymphoblastic leukemia, and hairy cell leukemia
[13-15]. Also, it has been detected in other major malig-
nancies, including colorectal, gastric, esophageal, lung,
kidney, and breast cancer while little expression is found
in normal tissues [16-21].
Several studies have investigated T cell responses to
cyclin D1 and their potential use for immunotherapy
[22-24]. Cyclin D1-specific cytotoxic T lymphocytes
(CTLs) have been demonstrated in cancer patients with
MCL and colorectal cancer [23,25,26]. CTLs specific for
cyclin D1 were successfully generated from HLA-A2his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ficiently recognized target cells pulsed with their cognate
peptide and cyclin D1 expressing tumor cell lines in an
HLA-A*0201-restricted manner. More importantly, HLA-
A*0201 matched, primary cyclin D1 positive tumor cells
were efficiently recognized by cyclin D1-specific CTLs [26].
This suggests that cyclin D1 could be considered as a can-
didate antigen for immunotherapy despite our limited
knowledge on the frequency and profile of cyclin D1-
specific T cells in MCL patients.
Numerous approaches for the therapeutic vaccination of
humans with cancer have been developed including autolo-
gous and allogeneic tumor cells (which are often modified
to express various cytokines), peptides, proteins, and DNA
vaccines (reviewed in [27]). Ex vivo-generated dendritic
cells (DCs) have been used as therapeutic vaccines in pa-
tients with metastatic cancer for over a decade [28]. Im-
portantly, a number of clinical studies have shown that
DCs can expand T cells specific for non-mutated self-
proteins that are overexpressed in cancer. The experimental
success of using DC-specific antibodies to target antigens
to individual DC subsets in conjunction with appropriately
chosen adjuvant has appealing potential for the design of
anti-cancer vaccines. Combined with a powerful adjuvant,
vaccinating with one or multiple tumor-derived antigens
coupled to DC-specific antibodies may amplify existing re-
sponses or break tolerance enabling the generation of pro-
tective responses. Studies to date demonstrate the targeting
delivery of tumor antigens to DCs and Langerhan’s cells
(LCs) [29] and the generation of therapeutic anti-tumor im-
munity [30] in animal models. More importantly, targeting
both tumor and control antigens to human DCs ex vivo
can lead to efficient antigen presentation and the subse-
quent generation of CD4+ T cell [31] and CD8+ T cell
[32,33] responses. Furthermore, certain lectin receptors, in-
cluding Dectin-1, LOX-1, and DC-SIGN, as well as other
DC surface molecules (e.g., CD40), can provide additional
activation signals to DCs [34-37].
Here, we have investigated specific T cell responses to
the whole cyclin D1 protein, focusing on identifying po-
tential dominant T cell epitopes. We found that both
healthy individuals and MCL patients have a broad rep-
ertoire of cyclin D1-specific T cells thus supporting the
utility of cyclin D1 as a tumor antigen for immunother-
apy. Subsequently, we have developed a novel vaccine
based on targeting cyclin D1 to DCs via the human DC
surface receptor CD40 and explore the immune re-
sponses generated by this novel vaccine.
Results
Cyclin D1-specific IFN-γ secreting T cells in PBMCs from
MCL patients
To assess the repertoire of cyclin D1-specific T cells, we in-
vestigated peripheral blood mononuclear cells (PBMCs)from five MCL patients (Table 1). A 15-mer overlapping
peptide library (71 peptides) covering the whole protein
was generated based on the cyclin D1 protein sequence
(Table 2). PBMCs from patient ACC-2000 were stimulated
with individual cyclin D1 peptides. Supernatants were har-
vested at 48 h, and cultures were continued for 8 days with
IL-2 supplement (Figure 1A, B shows the scheme of experi-
ment). At 48 h, we measured IL-2 and IP-10 secretion. As
shown in Figure 1A, cytokine responses at 48 h were low
with IP-10, nevertheless, peptide-specific peaks could be
detected. These included 15 peptides (marked in the figure)
inducing IP-10 production and six peptides inducing IL-2
secretion (Figure 1A).
At day 8 of culture, the cells were rested for 2 days
and restimulated for 48 h to analyze peptide-specific
cytokine responses. As shown in Figure 1B, 14/71 pep-
tides elicited strong IFN-γ response with up to 1 ng/ml
IFN-γ secreted in response to peptide 31. IL-2 was pro-
duced in response to ten peptides (Figure 1B).
Next, we wanted to analyze the frequency and type of
T cells specific to cyclin D1. CFSE-labeled PBMCs from
patient ACC-2000 were cultured with cyclin D1 pep-
tides, restimulated at day 11 with respective peptides,
and cytokine profiles were measured using multicolor
intracellular cytokine assay (ICS) (Figure 1C). Remark-
ably, 16/71 of the cyclin D1 peptides induced intracellu-
lar IFN-γ expression by CD4+ T cells (Figure 1C). This
suggests the presence of cyclin D1-specific Th1 cells in
MCL patients. Two out of 71 cyclin D1 peptides also in-
duced intracellular IFN-γ expression by CD8+ T cells
(Figure 1C). The peptides that could stimulate CD4+ and
CD8+ T cells were different (Figure 1C). ICS data were
further confirmed by the analysis of peptide-specific
cytokine responses assessed in the supernatants of cul-
tures restimulated for 48 h. There, a number of peptides
were able to elicit IFN-γ secretion (Figure 1C). Next,
Luminex® results reflecting the IFN-γ secretion into su-
pernatants were overlaid with ICS results reflecting the
phenotype of IFN-γ secreting T cells (Figure 1B). This
analysis clearly indicated that CD4+ and CD8+ T cells
recognize different cyclin D1 epitopes, and that CD4+ T
cell repertoire is much broader than that of CD8+ T
cells. The analysis of PBMCs from the same patient from
a second blood draw ACC-2003 obtained 3 months later
showed the same repertoire of IFN-γ secreting T cells
(Figure 2A, B). Thus, cyclin D1-specific T cell immunity
in MCL patients may be long lived.
Cyclin D1-specific T cells in a cohort of MCL patients
Having identified a broad repertoire of cyclin D1-specific
IFN-γ T cells in the PBMCs of one patient, we next ana-
lyzed PBMCs from a cohort of four additional MCL pa-
tients (Table 1). We used Luminex®-based cytokine
profiling upon PBMC restimulation as illustrated in












69 M T, Chemo - Remission A*0201B*1501*3503C*0303*1203 DRB1*0401*1401
DQB1*0503*0302
2. ACC-2038 54 M Chemo - Remission A*0201*2601B*3801*5101C*0701*1203 DRB1*1103*1301
DQB1*0301*0603
3. ACC-2805 58 M Chemo - Remission A*01*02 B*08*44 C* 05*07 *03(17)*07 DQB1*02
4. ACC-2501
ACC-2065a
57 M T, Chemo Chemo Persistent A*0101*0301 B*4402 C* 0501 DRB1*0401*1501
DQB1*0301*0602
5. ACC-2781 66 M No treatment - Just
diagnosis
A*01*31 B*08*40 (60) C*03*07 DRB1*03*04 DQB1*02*0302
T transplant, Chemo chemotherapy.
All the MCL patients are Caucasian.
aPatients 1 and 4 had two blood draws indicated with different patient ID.
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analyzed patients displayed cyclin D1-specific secretion
of IFN-γ. PBMCs from most of the patients showed
responses to a larger number of peptides (>10) except
PBMCs from the patient ACC-2501. While such
differences might be related to the precursor frequencyTable 2 15-mer cyclin D1 overlapping library
Peptide Position Sequence Peptide Position
1 1–15 MEHQLLCCEVETIRR 26 101–115
2 5–19 LLCCEVETIRRAYPD 27 105–119
3 9–23 EVETIRRAYPDANLL 28 109–123
4 13–27 IRRAYPDANLLNDRV 29 113–127
5 17–31 YPDANLLNDRVLRAM 30 117–131
6 21–35 NLLNDRVLRAMLKAE 31 121–135
7 25–39 DRVLRAMLKAEETCA 32 125–139
8 29–43 RAMLKAEETCAPSVS 33 129–143
9 33–47 KAEETCAPSVSYFKC 34 133–147
10 37–51 TCAPSVSYFKCVQKE 35 137–151
11 41–55 SVSYFKCVQKEVLPS 36 141–155
12 45–59 FKCVQKEVLPSMRKI 37 145–159
13 49–63 QKEVLPSMRKIVATW 38 149–163
14 53–67 LPSMRKIVATWMLEV 39 153–167
15 57–71 RKIVATWMLEVCEEQ 40 157–171
16 61–75 ATWMLEVCEEQKCEE 41 161–175
17 65–79 LEVCEEQKCEEEVFP 42 165–179
18 69–83 EEQKCEEEVFPLAMN 43 169–183
19 73–87 CEEEVFPLAMNYLDR 44 173–187
20 77–91 VFPLAMNYLDRFLSL 45 177–191
21 84–95 AMNYLDRFLSLEPVK 46 181–195
22 85–99 LDRFLSLEPVKKSRL 47 185–199
23 89–103 LSLEPVKKSRLQLLG 48 189–203
24 93–107 PVKKSRLQLLGATCM 49 193–207
25 97–111 SRLQLLGATCMFVAS 50 197–211and/or might be driven by ongoing treatment; neverthe-
less, this analysis demonstrates that MCL patients have
circulating memory T cells specific to cyclin D1. Thus,
both intracellular staining and secreted cytokine produc-
tions established the level of cyclin D1-specific T cells
induced by cyclin D1 peptides (Figure 3B). The secretionSequence Peptide Position Sequence
LLGATCMFVASKMKE 51 201–215 SMVAAGSVVAAVQGL
TCMFVASKMKETIPL 52 205–219 AGSVVAAVQGLNLRS
VASKMKETIPLTAEK 53 209–223 VAAVQGLNLRSPNNF
MKETIPLTAEKLCIY 54 213–227 QGLNLRSPNNFLSYY
IPLTAEKLCIYTDNS 55 217–231 LRSPNNFLSYYRLTR
AEKLCIYTDNSIRPE 56 221–235 NNFLSYYRLTRFLSR
CIYTDNSIRPEELLQ 57 225–239 SYYRLTRFLSRVIKC
DNSIRPEELLQMELL 58 229–243 LTRFLSRVIKCDPDC
RPEELLQMELLLVNK 59 233–247 LSRVIKCDPDCLRAC
LLQMELLLVNKLKWN 60 237–251 IKCDPDCLRACQEQI
ELLLVNKLKWNLAAM 61 241–255 PDCLRACQEQIEALL
VNKLKWNLAAMTPHD 62 245–259 RACQEQIEALLESSL
KWNLAAMTPHDFIEH 63 249–263 EQIEALLESSLRQAQ
AAMTPHDFIEHFLSK 64 253–267 ALLESSLRQAQQNMD
PHDFIEHFLSKMPEA 65 257–271 SSLRQAQQNMDPKAA
IEHFLSKMPEAEENK 66 261–275 QAQQNMDPKAAEEEE
LSKMPEAEENKQIIR 67 265–279 NMDPKAAEEEEEEEE
PEAEENKQIIRKHAQ 68 269–283 KAAEEEEEEEEEVDL
ENKQIIRKHAQTFVA 69 273–287 EEEEEEEEVDLACTP
IIRKHAQTFVALCAT 70 277–291 EEEEVDLACTPTDVR








Figure 1 (See legend on next page.)
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Figure 1 Mantle cell lymphoma patients display a broad repertoire of specific T cells to cyclin D1. PBMCs were isolated from a MCL patient (ACC-2000,
HLAA* 02010101*3201, B*1501*3503, C*0303*1203, DRB1*0401*1401, DQB1*0503*0302), then 1 × 106 cells per sample were stimulated with 71 individual
15-mer cyclin D1 peptides from Table 2. Median plus 5 multiplied median absolutedeviation (MAD) is considered a positive cutting line (shown as a red
dash line). (A) Supernatants were harvested to test IP-10 and IL-2 secretion after 48-h co-culture. NoP is a no peptide negative control. (B) Supernatants of
PBMCsafter 48-h boosting were harvested to test cytokine IL-2 and IFN-γ secretion by Luminex®. The cells without peptide were used as negative control.
Percentage of CD4+IFN-γ+ and CD8+IFN-γ+ population from IFN-γ intracellular staining (from (C) was shown in a two-line graph. (C) CFSE-labeled PBMCs
were stimulated with cyclin D1 for 8 days and rested in serum-free medium for 2 days before boosting by the same peptide. Intracellular staining of IFN-γ
was performed 6 h later. The cells without peptide were used as a negative control.
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confirmed by ICS in combination with CD154 staining.
As illustrated in Figure 3B, antigen-specific CD154+
CD4+ T cells secreted IFN-γ and IL-2 in the PBMCs
from patient ACC-2805. Similar patterns were found










































Figure 2 Long live of specific T cells to cyclin D1. (A) Another blood draw 3
IFN-γ cytokine secretion and percentage of CD4+IFN-γ+ and CD8+IFN-γ+ popu
positive cutting line (shown as a red dash line). (B) The potential cyclin D1
intracellular staining data are indicated on the protein sequence of cyclin
from two blood draws of the same MCL patient.from five healthy donors (Additional file 1: Table S1)
revealed sporadic detection of cyclin D1-specific T cell
responses (Additional file 2: Figure S1). Taken together,
these results indicate the presence of a broader reper-





























months later from the MCL patient ACC-2000, indicated as ACC-2003.
lation from IFN-γ intracellular staining were shown. MAD is considered a
epitopes that stimulate CD4+T cells to produce IFN-γ based on
D1. Data shown are two independent experiments by using PBMCs
Figure 3 (See legend on next page.)
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Figure 3 Cytokine profiles from different MCL patients. (A) The potential cyclin D1 epitopes that induced IFN-γ production in PBMCs obtained
from five MCL patients on protein sequence of cyclin D1, based on intracellular staining and Luminex® data. (B) Intracellular staining of IFN-γ, IL-2,
and CD40L were performed on a MCL patient ACC-2805 (HLA-A*01*02 B*08*44 C*05*07 DRB1*03*07 DQB1*02). The expressions from CD4+ gated
were shown. Similar patterns were found in other two patients.
Table 3 Potential cyclin D1 peptides for HLA-A*0201
molecules
Name Sequence Length (mer) Predictive binding scorea
P5-13 LLCCEVETI 9 6.0
P63-71 WMLEVVCEEQ 9 947.8
P151-159 NLAAMTPHD 9 743.7
P202-210 MVAAGSVVA 9 854.6
P204-212 AAGSVVAAV 9 703.7
P4-13 QLLCCEVETI 10 133.6
P21-30 NLLNDRVLRA 10 324.3
P58-67 KIVATWMLEV 10 255.9
P100-109 QLLGATCMFV 10 8.3
P101-110 LLGATCMFVA 10 184.0
P123-132 KLCIYTDNSI 10 246.9
P154-163 AMTPHDFIEH 10 981.0
P164-173 FLSKMPEAEE 10 508.5
P203-212 VAAGAVVAAV 10 580.3
P253-262 ALLESSLRQA 10 474.4
P57-67 RKIVATWMLEV 11 354.3
P94-104 VKKSRLQLLGA 11 582.3
P99-109 LQLLGATCMFV 11 711.1
P106-116 CMFVASKMKET 11 339.2
P123-133 KLCIYTDNSIR 11 362.3
P154-164 AMTPHDFIEHF 11 904.8
P158-168 HAFIEHFLSKM 11 577.7
P202-212 MVAAGSVVAAV 11 746.2
P208-218 VVAAVQGLNLR 11 442.9
aPredictions (ann methods)—low IC50 values (nM) = good binder.
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epitopes
Despite detecting cyclin D1-specific T cells, our analysis,
thus far, showed a broad CD4+ T cell repertoire but a ra-
ther narrow CD8+ T cell repertoire in MCL patients.
This could be due to the length of the peptides as class I-
dependent CD8+ cells respond better to 8-12-mers.
Because CTLs are a major effector arm of anti-tumor im-
munity, we analyzed in greater detail on the induction of
cyclin D1-specific CD8+ T cells from PBMCs of healthy
donors. To this end, we selected cyclin D1 peptides which
could induce strong IFN-γ production as described above
and then screened the cyclin D1 sequences for their bind-
ing affinity to HLA-A*0201 using peptide-binding data-
bases (http://www.immuneepitope.org). Table 3 shows the
sequence of human cyclin D1 peptides that could poten-
tially bind to HLA-A*0201 as deduced by computational
predictive binding scores.
The binding affinity of cyclin D1 peptides (Table 3) to
HLA-A*0201 molecules was determined using the HLA-
A2 TAP-deficient T2 lymphoma cell line, which enhances
HLA-A2 expression when exposed to exogenous HLA-
A2-binding peptides. This assay confirmed that P4–13,
P58–67, P100–109, P123–132, P99–109, and P202–212 can bind
HLA-A*0201 molecules (Figure 4A). To test CD8+ T cell
responses, CD8+ T cells from a healthy donor (ND239
HLA-A*0201) were expanded by stimulating with DCs
loaded with cyclin D1 peptides. Then, T cells were restim-
ulated with peptide-pulsed T2 cells at 37°C for 36 h to test
the cytokine production in the supernatant by Luminex®.
As shown in Figure 3B, among the seven cyclin D1
peptides able to bind HLA-A*0201 on T2 cells, only
P58–67 (KIVATWMLEV), P57–67 (RKIVATWMLEV),
and P99–109 (LQLLGATCMEV) could induce cytokine
production. Cells pulsed with no peptide were used
as negative controls in binding affinity studies and
the cytokine release assay (Figure 4A, B). Thus, three
cyclin D1 peptides P58–67, P57–67, and P99–109 could
induce potent CD8+ T cell responses.
Next, we assessed whether the identified CD8+ T cell
epitopes can be cross-presented to elicit specific CTLs.
There, enriched HLA-A*0201+ CD8+ T cells were ex-
panded by GM-CFS/IFN-DCs pulsed with MCL cell line
Granta 519 dying bodies. After a single round of stimu-
lation and 10-day culture, the T cells were tested for
their capacity to kill cyclin D1-expressing target cells
using a standard 51Cr-release assay. Figure 4C shows
that CD8+ T cells could kill Granta 519 MCL cells thatwere used as the antigenic cargo to load the DCs. Con-
trol K562 cells were not killed suggesting CTL lysis. This
was further confirmed by the capacity of elicited CTLs
to kill T2 cells pulsed with cyclin D1 peptide P99–109
(Figure 4C). Thus, this peptide can be cross-presented
and recognized by CD8+ T cells. Though cyclin D1
peptides P58–67 and P57–67 were able to induce cytokine
secretion (Figure 4A, B), no killing was observed
for these two individual peptides loaded on T2 cells
(Figure 4C).
Recombinant fusion protein anti-CD40-cyclin D1
efficiently expands specific CD8+ T cells
CD40 is a co-stimulatory molecule belonging to the
tumor necrosis factor receptor family and is expressed
Figure 4 (See legend on next page.)
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Figure 4 Identifying dominant HLA-A*0201-restricted cyclin D1 T cell epitopes. (A) Binding capacity for cyclin D1 peptides to HLA-A*0201 molecules
on T2 cells. T2 cells were cultured with predicted cyclin D1 peptides which have high binding affinity to HLAAA* 0201 (list in Table 3), in RPMI1604
without FCS for 18 h, and subsequently stained for cell surface expression of MHC class I. Up-regulation of HLA-A2 expression after binding with
specific peptides was represented as median fluorescence intensity (MFI). Sequences of positive peptides are shown. (B) IFN-DCs primed by the
individual cyclin D1 peptide as (A) were co-cultured with enriched CD8+ T cells for 10 days. Then, cells were boosted with the same peptide pulsed T2
cells at 37°C for 36 h, thereafter, supernatant was harvested, and the cytokines production were tested by Luminex®. Sequences of positive peptides
are shown. (C) Enriched CD8+ T cells from a healthy donor ND239 (HLA-A*0201) were stimulated with autologous IFΝ-DCs pulsed with MCL
lymphoma cell dying bodies (Granta 519) and treated with LPS for 6 h. Ten days later, induced specific CTLs were tested in a standard 4-h
51Cr release assay. Target cells used were cyclin D1 peptide P58–67 KIVATWMLEV-pulsed T2 cells, P57–67 RKIVATWMLEV-pulsed T2 cells,
P99–109 QLLGATCMFV-pulsed T2 cells, non-pulsed T2 cells, cyclin D1
+HLA-A*0201+ MCL lymphoma cell line Granta 519, and K562 as natural
killing activity controls.
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[38,39]. Anti-CD40 mAbs were able to facilitate the mat-
uration of DCs, and DCs mediated T cell activation
[40-42]. Delivery of antigen via mAb to CD40 has been
shown to induce antigen-specific immune responses and
provide protection against cancer [43], as well as control
HIV infection in vitro [44]. Thus, to explore the poten-
tial of this novel vaccine, large cyclin D1 domains were
fused to the heavy chain of anti-CD40 Abs (anti-CD40-
cyclin D1 mAb) along with isotype control, IgG4 mAbs.
Figure 5A shows the construction of these fusion pro-
teins. Domain 1 was fused to DC receptor CD40 or
isotype control IgG4, generating anti-CD40-cyclin D1-
pepA and IgG4-cyclin D1-pepA protein. Domains 2, 3,
and 4 were fused to DC receptor CD40 or isotype control
IgG4, generating anti-CD40-cyclin D1-pepB and IgG4-
cyclin D1-pepB protein. Together, these two anti-CD40
fusion proteins carried the entire cyclin D1 sequence.
We next tested whether cyclin D1 could be presented
to the DC surface by the fusion proteins. GM-CSF/IFN
alpha monocyte-derived DCs (IFN-DCs) were first incu-
bated with fusion proteins for 30 min on ice to prevent
internalization, cyclin D1 presented on the surface of
DCs was detected by anti-human IgG Abs (Figure 5B),
and confirmed by using anti-human cyclin D1 Ab
(Figure 5C). Anti-human-cyclin D1 mAb (clone: G124-
326) recognized anti-CD40-cyclin D1-pepB, but not
anti-CD40-cyclin D1-pepA, IgG4-cyclin D1-pepA, and
IgG4-cyclin D1-pepB (Figure 5C). Anti-human-cyclin
D1 mAb is a monoclonal antibody, which recognized
full length cyclin D1, so it may not identify the short
part of cyclin D1 presented by anti-CD40-cyclin D1-pepA.
Isotype control IgG4-cyclin D1-pepA and IgG4-cyclin
D1-pepB could not present to the DC surface.
In addition, the expression of activation markers
and co-stimulatory molecules (CD83, CD86, CD80,
HLA-DR, and CCR7) on IFN-DCs was significantly
increased by 48 h after co-culture with anti-CD40-cyclin
D1 Abs (Figure 5D). This data demonstrated the activating
properties of recombinant anti-CD40-cyclin D1 fusion
proteins compared to the matching IgG4 control fusion
proteins.Subsequently, the targeting ability of CD40-cyclin D1
recombinant fusion protein to DCs was investigated for
the capacity to activate cyclin D1-specific T cells from
healthy individuals. IFN-DCs targeted with anti-CD40-
cyclin D1 mAb expanded a broad repertoire of cyclin
D1-specific CD4+ and CD8+ T cells (Figure 6A, B).
To examine the cytolytic capability of cyclin D1-
specific CD8+ T cells, we assessed the functional capacity
of prototype vaccine-expanded CD8+ T cells to produce
effector cytokines, cytolytic factors, and degranulation
capacity as determined by externalization of CD107a.
IFN-DC presented anti-CD40-Cyclin D1 to T cell
cultures from a healthy donor; in response to peptide
challenge, cyclin D1-specific CD8+ T cells positive for
CD107a and granzyme B with IFN-γ were induced
(Figure 6A, B).
Collectively, these data demonstrate the capacity of
anti-CD40-cyclin D1 recombinant fusion proteins to
expand cyclin D1-specific CD4+ and CD8+ T cells. Cur-
rently, the anti-CD40-cyclin D1 recombinant vaccine is
being tested in vivo in non-human primates. This strat-
egy will facilitate the development of a mantle cell
lymphoma vaccine.Discussion
The better understanding of anti-tumor immune
response and tumor immune escape mechanisms and
the exploration of new ways for different effects and
mechanisms of tumor immunotherapy and immunother-
apy will facilitate new and innovative approaches to
human tumor immunotherapy. Immunotherapy is mov-
ing to the vanguard of cancer therapy. Cancer immuno-
therapy is being increasingly used to drive the immune
system to treat tumors [45], and tumor antigens are the
most appropriate targets for cancer immunotherapy
[46]. The antigen of interest can be used to vaccinate as
a whole protein or with synthetic peptides derived from
this protein. Presentation of T cell epitopes on MHC
complexes can successfully induce T cell responses. T
cells specific to subdominant epitopes have been shown
to participate in anti-tumor immune responses [47].
Figure 5 Characterization of recombinant cyclin D1 fusion proteins. (A) The construction of cyclin D1 fused to DC receptor CD40 recombinant
IgG4 mAb or non-DC binding IgG4 as a control. The sequence of the different human cyclin D1 protein domains is shown in different colors.
(B, C) Anti-CD40-cyclin D1 Abs detected on the surface of monocytederived IFN-DCs. Flow cytometry staining of IFN-DCs with anti-human IgG
(B), antihuman cyclin D1 (C), or anti-mouse IgG isotype control mAbs (C). (D) The expression of several molecules (CD86, CD80, CD83, HLA-DR,
and CCR7) on the IFN-DCs was significantly increased after co-culture with anti-CD40-cyclin D1 fusion proteins for 48 h, compared with co-culture
with IgG4-cyclin D1 control proteins. The data from a representative of three independent experiments are shown; different donors showed
similar results.
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(MAGE-1)-derived peptide-based vaccine was reported in
1996 [48]. Afterward, numerous clinical trials of peptide
vaccines have been carried out to assess the ability of these
vaccines to induce clinical responses in different cancerpatients, and some promising clinical responses have been
observed. A number have already received FDA approval,
including a personalized peptide vaccination protocol
[49]. Peptides recognized by CTLs or helper T cells are
generally derived from fragments of tumor antigen
Figure 6 (See legend on next page.)
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Figure 6 Targeting cyclin D1 to DCs via CD40 elicits cyclin D1-specific CD4+ and CD8+T cell responses. (A) 5 x103 IFN-DCs were loaded with 3
μg/ml recombinant cyclin D1 fusion proteins or control IgG-cyclin D1. After 8 h, CFSE-labeled autologous enriched CD3+T cells were co-cultured
for 7 days then added the same amount of cyclin D1 fusion protein or control IgG-cyclin D1-loaded IFN-DCs cultured for another 7 days. Cells
were boosted by 71 of 15-mer cyclin D1 peptides following 2-day resting in serum-free medium. Intracellular staining of IFN-γ was performed 8 h
later. The cells without peptide boosting were used as a negative control. The percentage of IFN-γ+CFSE− cells in gated CD4+ T cells and
IFN-γ+Granzyme B+ cells in gated CD8+ T cells were indicated. This data is a representative of three independent experiments of a healthy donor
ND257 (HLA-A*0201). (B) Intracellular staining of IFN-γ/CD107a performed in another healthy donor ND239 (HLA-A*0201) was shown. Percentage
of IFN-γ+CD107a+ cells from CD8+ gated is indicated.
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were shown to contribute to the production of these pep-
tides [50]. A database containing human antigenic pep-
tides which aims to guide scientists and clinicians
searching for appropriate cancer vaccine candidates is
available and is constantly being updated [46].
Here, we expanded cyclin D1-specific IFN-γ secreting
T cells in PBMCs from MCL patients, as well as from
healthy donors. A number of cyclin D1 peptides were
able to stimulate IFN-γ production and showed a broad
CD4+ T cell repertoire but a narrow CD8+ T cell reper-
toire. To do more analysis, crucial for an effective vac-
cine therapy, we screened peptides based on MHC-
binding algorithms and cytokine secretion. Three cyclin
D1 peptides P58–67, P57–67, and P99–109 induced potent
CD8+ T cell responses. One of these peptides, P99–109,
could be cross-presented and recognized by CD8+ T
cells. In accord with our results, HLA-A*0201-binding
cyclin D1 epitopes were also previously reported [23,24,26].
The HLA-DR4-restricted T cell epitope P198–212: NPP
SMVAAGSVVAAV derived from cyclin D1 epitope was
identified by mass spectrometry [22]. Thus, our results
highlight the importance of verifying the functional
peptide sequences in vaccines. The finding that immune
reactivity against cyclin D1 was also found in healthy
donors could mean that cancer patients have a high
frequency of cyclin D1-specific T cell precursors in the
blood, potentially leading to a higher efficacy of cyclin
D1-targeted anti-tumor vaccination.
Dendritic cells (DCs) are specialized in antigen pro-
cessing and presentation. DC-based experimental cancer
vaccines have shown some success in patients with
lymphoma and other cancers. Numerous receptors are
expressed on DCs, including three categories: receptor
kinases, toll-like receptors (TLRs), and C-type lectin
receptors. By targeting these DC receptors, a more
competent approach of delivering antigens in DC-based
anti-cancer immunotherapy is becoming a promising
vaccination strategy. The specific targeting of antigens
to DCs in vivo could enhance potent antigen-specific
CD4+ and CD8+ T cell-mediated immunity [51-53]. DC
targeting not only assists the delivery of an antigen but
also potentially provides an activation signal by targeting
activating DC receptor antibodies [45].In this context, cyclin D1 is a promising tumor-
associated antigen (TAA) for MCL. It is consistently
overexpressed in virtually all MCL patients. Moreover,
the presence of cyclin D1-specific CD8+ T cells in MCL
patients is proven. Our previous study using anti-
CD40.HIV5pep antibody, which has a physical linkage
between the five long HIV peptides from Gag, Nef, and
Pol with the CD40-targeting antibody, could also induce
HIV-specific T cells in vitro [44]. In order to develop a
specific immune response against MCL, recombinant
cyclin D1 antigen carried by an anti-DC receptor vehicle
CD40 was delivered to IFN-DCs for MHC class-I cross-
presentation in T cell co-cultures. This resulted in the
expansion of antigen-specific CD8+ T cells, which were
evaluated by measuring the production of cytokines fol-
lowing peptide stimulation. In response to peptide chal-
lenge, most antigen-specific CD8+ T cells expressed
granzyme B and CD107a with IFN-γ, establishing the
cytotoxic capability of cyclin D1-specific CD8+ T cells.
Antigen-specific CD4+ T cells also could expand via this
prototype vaccine. Thus, our results demonstrated that
targeting cyclin D1 to DCs could efficiently induce and
activate cyclin D1-specific T cells.
Taken together, these approaches will facilitate the
development of a novel DC vaccine for MCL. Mounting
a potent cellular immune response in MCL patients is
expected to bring better clinical benefits to patients.
Materials and methods
Study subjects
Five healthy donors and five MCL patients were studied.
Their demographics and HLA types are listed in Table 1.
All MCL patients are cyclin D1 positive. Apheresis and
blood draws were obtained according to IRB-approved
protocol (002–108) at Baylor Research Institute (Dallas,
TX). All donors signed informed consent forms. Peripheral
blood mononuclear cells (PBMCs) were purified by
Ficoll (Amersham Biosciences, Pittsburgh, PA) density
gradient centrifugation and cryopreserved until use.
Total T cells or CD8+ T cells were enriched by negative
selection following manufacture protocols with an EasySep
Human T cell Enrichment kit or EasySep Human CD8+
T cell Enrichment kit (Stem Cell Technologies Inc.) to
purity ≥98%.
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The overlapping 15-mer cyclin D1 peptide library
(Table 2) was staggered every four amino acids along the
entire cyclin D1 sequence and generated at Mimotopes
(Clayton, Australia). Peptides were dissolved in 5%
acetonitrile (Sigma) at 10 mM and stored at −80°C.
Media and reagents
Complete culture medium (CM) consisted of RPMI 1640
medium (Invitrogen, Carlsbad, CA), 1% L-glutamine
(Sigma), 1% penicillin/streptomycin (Sigma), 50 mM 2-
mercaptoethanol (Sigma), 1% sodium pyruvate (Sigma),
1% nonessential amino acids (Sigma), and 10% heat-
inactivated FBS (fetal bovine serum, GIBCO). For T cell
cultures, FBS was replaced by 10% heat-inactivated human
serum AB (Gemcell). IL-2 (Genzyme) was used at 100 IU/ml.
FITC mouse anti-human cyclin D1 antibody (G124-326)
was purchased from BD Pharmingen.
Cell lines
Granta 519 (mantle cell lymphoma cell line), K562, and
T2 (HLA-A2-positive cell line) cells were purchased
from the American Type Culture Collection (Manassas,
VA). Cell lines were cultured in CM.
Intracellular cytokine assay
Cultured PBMCs were restimulated with individual cyc-
lin D1 15-mer peptides for 2 h. Then, Golgi-plug (BD
Pharmingen) was added to the cultures and followed by
another 4-h culture. After a total 6 h of stimulation, cells
were harvested, surface stained with CD4 and CD8 mAbs,
then fixed and permeabilized with Cytofix/Cytoperm
solution (BD). Finally, the cells were stained intracellu-
larly with anti-IFN-γ mAb (BD Pharmingen). The cells
were acquired on Canton II or LSRII flow cytometer
(BD Bioscience, San Jose, CA) and analyzed using
FlowJo software (Treestar, Ashland, OR). When cultured
T cells were analyzed, IFN-DCs were first loaded with
cyclin D1 15-mer peptides for 1 h and then used to
stimulated T cells.
Peptide binding assay
The human TAP-deficient HLA-A*0201+ T2 cell line
was used to measure the binding ability of cyclin D1
peptides to HLA-A*0201 molecules as described previ-
ously [54]. Briefly, 1 × 105 T2 cells per well were incu-
bated in a 96-well plate with or without individual
peptides at a concentration of 25 μg/ml overnight. Then
the cells were harvested, washed twice with FACS buffer,
and stained with a PE-conjugated anti-HLA-A2 antibody
(BB7.2; BD Pharmingen, San Diego, CA). The mean
fluorescence intensity of HLA-A2 staining was analyzed
by LSRII.Analysis of T cell responses by analysis of cytokine
release
T2 cells were pre-loaded with 10-μM peptides for 2 h,
washed with PBS twice, then cultured with effector cells
at 1:1 ratio in a total volume of 200 μl medium with
PMA (phorbolyristate acetate, 100 ng/ml). Culture su-
pernatants were harvested 36 h later and tested for IL-2,
IFN-γ, and IP-10 production via cytokine multiplex
analysis.
Preparation of killed MCL lymphoma cells
A 2 × 105 cells/ml of the MCL cell line Granta 519 was
treated with Velcade (Bortezomib, LC Laboratories) at
0.2 μg/ml for 17 h at 37°C. The obtained killed Granta
519 cells, a mixture of apoptotic and necrotic cells, were
prepared in batches and frozen and stored in liquid
nitrogen. Annexin V and propidium iodide (PI) staining
was used to measure death of the lymphoma cells.
Generation of CTLs and cytotoxicity assay
IFN-DCs were generated from elutriated monocytes by
culturing in CellGenix medium (CellGenix) supple-
mented with 100 ng/ml human granulocyte-monocyte
colony-stimulating factor (GM-CSF, Berlex Laboratories
Inc.) and 500 U/ml IFN-α (INTRONA, Schering Corp)
for 3 days. IFN-DCs were loaded with killed Granta 519
cells in a 2:1 ratio for 6 h, then cultured with autologous
enriched CD8+ T cells at a 1:25 ratio, and supplemented
with IL-7 (10 IU/ml) and IL-2 (10 IU/ml) at day 3 and
IL-2 only at the second week. T cells were restimulated
on day 7. The CTL activity was measured in a standard
4-h 51C-release assay at day 14. Briefly, T2 cells were
loaded with or without 10-μM peptide for 2 h. Target cells
were labeled with 51Cr (NEN Life Science Products,
Boston, MA) for 1 h, washed then co-cultured with CTLs
for 4 h. Specific lysis was calculated using the following
formula: (where cpm is counts per minute): % release =
100 × (cpm experiment–cpm spontaneous release)/(cpm
maximum release–cpm spontaneous release).
Generation of recombinant fusion proteins
Antigen coding regions were transferred to vectors for
stable transfection of CHO-S cell lines for expression and
subsequent purification of anti-CD40-cyclin D1-pep and
control hIgG4-cyclin D1-pep as described previously [55].
The control hIgG4 H chain variable and constant region
was gb|BC025985.1| residues 19–1437 with T778C,
A780C, and CTG at 779–801 to GAA changes. The con-
trol hIgG4 L chain variable and constant region was de-
rived from clone CS0DI041YP06 (Invitrogen). Two sets of
antibody-antigen fusion proteins were produced, one with
cyclin D1 (NP_444284.1) residues 1–48 appended to the
H chain C-terminus (pepA) and the other with residues
49–295 appended to the H-chain C-terminus (pepB).
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tained when the cyclin D1 peptide regions were flanked by
the glycosylated flexible linker sequences ASQTPTNTIS
VTPTNNSTPTNNSNPKPNPAS and ASTNGSITVAATAP
TVTPTVNATPSAAAS [44].Accession codes of CD40-targeting antibody
The 12E12 hybridoma is ATCC PTA 9854. The chimeric
CD4012E12 L and CD4012E12 H chain sequences are
GenBank HQ738667 and HQ738666, respectively.Statistical analysis
The local median regression method was used to set up
a positive cutting line for cytokine production. Median
plus 5 multiplied median absolute deviation (MAD) was
considered statistically significant [56]. Unless otherwise
indicated, the value of median plus 5 MAD was shown.Additional files
Additional file 1: Table S1. HLA types of healthy donors.
Additional file 2: Figure S1. Cyclin D1-induced T cell responses in a
healthy donor. PBMCs isolated from a healthy donor (ND239, HLA-A*0201*01
B*08*51/78 C*07 DRB1*0301*11 DQB1*02*03) were stimulated with the
overlapping 15-mer cyclin D1 peptide library. Median plus 5 multiplied MAD is
considered as a positive cutting line. (A) Supernatants were harvested to test
cytokine secretion after 48-h co-culture. NoP is a no peptide negative control.
(B) PBMCs were stimulated with cyclin D1 for 8 days and rested in serum-free
medium for 3 days before boosting by the same peptide. Intracellular staining
of IFN-γ was performed 6 h later. The cells without peptide were used as a
negative control. Percentage of CD4+IFN-γ+ and CD8+IFN-γ+ population from
IFN-γ intracellular staining was shown in a two-line graph. Medium plus 5
multiplied MAD is considered as a positive cut-off line (shown as a red dash
line for CD4+ T cells and a blue dash line for CD8+ T cells).
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